Press Releases June 4, 2026 08:30 AM

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions to attend Planet MicroCap Conference June 16-18, showcasing rapid fingerprint-based drug testing technology

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
INBS

Intelligent Bio Solutions Inc., a Nasdaq-listed medical technology company specializing in rapid, non-invasive testing solutions, announced participation in the Planet MicroCap Conference in Las Vegas from June 16-18, 2026. The management team will present and hold one-on-one investor meetings, highlighting their Intelligent Fingerprinting Drug Screening System designed for hygienic, quick drug detection in various industries.

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
INBS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The company will present at the Planet MicroCap Conference in Las Vegas on June 17, 2026.
  • Showcases Intelligent Fingerprinting Drug Screening System with results under ten minutes.
  • Targets safety-critical industries requiring rapid, non-invasive drug testing, including construction, manufacturing, transport, mining, and drug treatment sectors.

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.

Conference Details
Date: June 16-18, 2026
Location: Bellagio Hotel & Casino, Las Vegas
Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT
Presentation Location: Track 7 – Donatello 3
Registration: Interested investors can register to attend here
Webcast: Viewable here
Booth: 413

The Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedule a meeting with the INBS management team, please contact your Planet MicroCap representative or email KCSA Strategic Communications at INBS@kcsa.com.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. 

For more information, visit: https://ibs.inc/ 

Company Contact 
Intelligent Bio Solutions Inc.  
info@ibs.inc 

Investor & Media Contact  
Valter Pinto, Managing Director  
KCSA Strategic Communications  
PH: (212) 896-1254  
INBS@kcsa.com 


Risks

  • Market adoption of new fingerprint-based drug testing technology may be slow or face regulatory hurdles.
  • Dependence on expanding customer base outside the U.S. poses geographic market risks.
  • Competition from existing drug testing methods and companies could impact growth potential.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026